Lv4
618 积分 2021-03-03 加入
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
6天前
已完结
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
6天前
已完结
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
6天前
已完结
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
6天前
已完结
Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data
22天前
已完结
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial
1个月前
已完结
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial
2个月前
已完结
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
2个月前
已完结
Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects
2个月前
已完结
Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment
2个月前
已完结
皖公网安备34019202002308
